Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Keith Michael Gottesdiener M.D., Ph.D. | President, CEO, Secretary & Director | 1.06M | -- | 1954 |
| Dr. Ann L. Lee Ph.D. | Chief Technical Officer | 684.78k | -- | 1962 |
| Dr. Jeremy S. Duffield M.D., Ph.D. | Chief Scientific Officer | 680.65k | -- | 1968 |
| Dr. Andrew Anzalone M.D., Ph.D. | Co-Founder & Head of Prime Editing Platform | -- | -- | 1987 |
| Dr. David R. Liu Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | -- |
| Dr. Allan Reine M.D. | Chief Financial Officer | -- | -- | 1975 |
| Dr. Meredith Goldwasser | Senior VP and Head of Strategy & Corporate Operations | -- | -- | 1971 |
| Ms. Carman Alenson CPA, M.B.A. | Senior VP of Finance & Chief Accounting Officer | -- | -- | 1966 |
| Dr. Karen Brown J.D., Ph.D. | Senior Vice President of Intellectual Property & Legal Affairs | -- | -- | -- |
| Ms. Niamh Alix | Chief Human Resources Officer | -- | -- | -- |
Prime Medicine, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 234
Description
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
December 18, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission